Fluidx Medical has announced that the first patient has been treated with the Ultra embolic device. The Ulutra device is intended for embolization of hypervascular tumours and blood vessels to occlude blood flow for controlling bleeding in the peripheral vasculature.
The Ultra embolic device was successfully used to treat an angiomyolipoma (AML) tumour. AMLs are the most common, solid renal tumour affecting between 0.3% and 0.6% of the global population.
“We are pleased with how controlled the material delivery was,” said Andrew Holden, principal investigator at Auckland City Hospital in Auckland, New Zealand. “A testament to the technology, we felt comfortable delivering it in a difficult anatomical setting. We could see the material very well as it filled the vessel segment, completely blocking blood flow to the target area.”
“The Ultra embolic device was designed to provide maximum control to the physician,” said Russ Bjorklund, vice president, Fluidx Medical. “Embolics should have consistent performance to maximise patient safety, be fast to prepare to reduce case times, and deliver complete results.”
According to the company, unlike other embolic devices, the Fluidx Medical Technology portfolio does not use toxic dimethyl sulfoxide (DSMO) or other precursors, glue catheters into the body, require special delivery systems, or need special mixers and preparation stations.
GPX, Ultra, and Impass embolic devices are under development, described and shown for research, educational, and engineering use only, and do not have marketing clearance or approval in any market at this time.
